share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Obenshain Andrew

SEC announcement ·  Jan 9 00:00
Summary by Moomoo AI
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 3,162 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.4294 each, resulting in a total sale value of approximately $4,519.76. Following the sale, Obenshain's direct holdings in the company amount to 287,972 shares of common stock.
Andrew Obenshain, President and CEO of bluebird bio, Inc., completed a sale of 3,162 shares of common stock on January 5, 2024. The transaction was carried out on the open market with the shares sold at a price of $1.4294 each, resulting in a total sale value of approximately $4,519.76. Following the sale, Obenshain's direct holdings in the company amount to 287,972 shares of common stock.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more